Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:305
Name carcinoma
Definition A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids DOID:6570 DOID:2428
Path disease disease of cellular proliferation cancer cell type cancer carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ERBB2 over exp Margetuximab carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Recruiting
NCT01148849 Phase I Margetuximab Safety Study of MGAH22 in HER2-positive Carcinomas Active, not recruiting
NCT01427322 Phase I Lapatinib Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease Terminated
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting
NCT02637531 Phase I Pembrolizumab IPI-549 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Active, not recruiting
NCT02648490 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers Completed
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Active, not recruiting
NCT03094169 Phase I AVID100 AVID100 in Advanced Epithelial Carcinomas Recruiting
NCT03391973 Phase II Pembrolizumab Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP) Recruiting
NCT03396471 Phase II Pembrolizumab Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary Recruiting
NCT03570619 Phase II Ipilimumab + Nivolumab Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT) Recruiting
NCT03852511 Phase I NG-350A First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE) Recruiting
NCT04053283 Phase I NG-641 First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector Recruiting
NCT04147819 Phase I BAY2701439 A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein Recruiting